JP2019507599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507599A5 JP2019507599A5 JP2018546483A JP2018546483A JP2019507599A5 JP 2019507599 A5 JP2019507599 A5 JP 2019507599A5 JP 2018546483 A JP2018546483 A JP 2018546483A JP 2018546483 A JP2018546483 A JP 2018546483A JP 2019507599 A5 JP2019507599 A5 JP 2019507599A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- group
- trac
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 35
- 108090000623 proteins and genes Proteins 0.000 claims 27
- 210000001744 T-lymphocyte Anatomy 0.000 claims 18
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 14
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 claims 14
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims 12
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 12
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 claims 12
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 12
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 claims 12
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 12
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims 12
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 12
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 claims 12
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims 12
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 10
- 108020005004 Guide RNA Proteins 0.000 claims 9
- 238000012986 modification Methods 0.000 claims 9
- 230000004048 modification Effects 0.000 claims 9
- 230000008685 targeting Effects 0.000 claims 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 6
- 101710163270 Nuclease Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 102000004389 Ribonucleoproteins Human genes 0.000 claims 4
- 108010081734 Ribonucleoproteins Proteins 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 4
- 210000002865 immune cell Anatomy 0.000 claims 4
- 210000000822 natural killer cell Anatomy 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 3
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- -1 TRBC Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 238000004520 electroporation Methods 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 210000003738 lymphoid progenitor cell Anatomy 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004533 Endonucleases Human genes 0.000 claims 1
- 108010042407 Endonucleases Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 241000605861 Prevotella Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 108091081024 Start codon Proteins 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023046534A JP2023089005A (ja) | 2016-03-04 | 2023-03-23 | がん免疫療法のためのｃｒｉｓｐｒ－ｃｐｆ１関連方法、組成物および構成要素 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662304057P | 2016-03-04 | 2016-03-04 | |
| US62/304,057 | 2016-03-04 | ||
| PCT/US2017/020598 WO2017152015A1 (en) | 2016-03-04 | 2017-03-03 | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023046534A Division JP2023089005A (ja) | 2016-03-04 | 2023-03-23 | がん免疫療法のためのｃｒｉｓｐｒ－ｃｐｆ１関連方法、組成物および構成要素 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507599A JP2019507599A (ja) | 2019-03-22 |
| JP2019507599A5 true JP2019507599A5 (enExample) | 2020-04-16 |
| JP7251980B2 JP7251980B2 (ja) | 2023-04-04 |
Family
ID=58358928
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546483A Active JP7251980B2 (ja) | 2016-03-04 | 2017-03-03 | がん免疫療法のためのｃｒｉｓｐｒ－ｃｐｆ１関連方法、組成物および構成要素 |
| JP2023046534A Pending JP2023089005A (ja) | 2016-03-04 | 2023-03-23 | がん免疫療法のためのｃｒｉｓｐｒ－ｃｐｆ１関連方法、組成物および構成要素 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023046534A Pending JP2023089005A (ja) | 2016-03-04 | 2023-03-23 | がん免疫療法のためのｃｒｉｓｐｒ－ｃｐｆ１関連方法、組成物および構成要素 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12325854B2 (enExample) |
| EP (1) | EP3423580A1 (enExample) |
| JP (2) | JP7251980B2 (enExample) |
| KR (4) | KR102587132B1 (enExample) |
| CN (1) | CN109312340A (enExample) |
| AU (2) | AU2017226172B9 (enExample) |
| CA (1) | CA3016331A1 (enExample) |
| IL (2) | IL291971B2 (enExample) |
| MX (2) | MX2018010484A (enExample) |
| SG (1) | SG11201807538PA (enExample) |
| WO (1) | WO2017152015A1 (enExample) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| CN109803977B (zh) | 2016-08-17 | 2023-03-17 | 菲克特生物科学股份有限公司 | 核酸产品及其施用方法 |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| CN108690845B (zh) | 2017-04-10 | 2021-04-27 | 中国科学院动物研究所 | 基因组编辑系统和方法 |
| EP3612632A2 (en) | 2017-04-18 | 2020-02-26 | Yale University | A platform for t lymphocyte genome engineering and in vivo high-throughput screening thereof |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| US20200216805A1 (en) * | 2017-09-18 | 2020-07-09 | Edigene Inc. | Gene editing t cell and use thereof |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| CN111556893A (zh) * | 2017-11-06 | 2020-08-18 | 爱迪塔斯医药股份有限公司 | 免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分 |
| CA3082331A1 (en) * | 2017-11-16 | 2019-05-23 | Mogam Institute For Biomedical Research | Transformed human cell and use thereof |
| EP3724326A1 (en) * | 2017-12-11 | 2020-10-21 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| CN111788307A (zh) | 2018-03-12 | 2020-10-16 | 南京北恒生物科技有限公司 | 工程化的嵌合向导rna及其用途 |
| JP7611564B2 (ja) * | 2018-03-13 | 2025-01-10 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Ｃａｓ９塩基エディターを使用するリンパ球造血系操作 |
| EP3781678A4 (en) * | 2018-04-18 | 2022-06-01 | Yale University | Compositions and methods for multiplexed tumor vaccination with endogenous gene activation |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| US20210363206A1 (en) * | 2018-06-18 | 2021-11-25 | The Regents Of The University Of California | Proteins that inhibit cas12a (cpf1), a cripr-cas nuclease |
| US20210322473A1 (en) * | 2018-07-18 | 2021-10-21 | The General Hospital Corporation | Modified t cells and methods of their use |
| US20200080056A1 (en) * | 2018-09-06 | 2020-03-12 | The Trustees Of The University Of Pennsylvania | CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell Therapy |
| WO2020057668A1 (zh) * | 2018-09-21 | 2020-03-26 | 科济生物医药（上海）有限公司 | 基于CRISPR/Cas系统对细胞进行基因编辑的方法 |
| AU2019362879A1 (en) * | 2018-10-16 | 2021-05-27 | Intellia Therapeutics, Inc. | Compositions and methods for immunotherapy |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| JP7546197B2 (ja) * | 2019-01-04 | 2024-09-06 | フル サークルズ セラピューティクス，インコーポレイティド | 環状一本鎖ｄｎａを用いた標的化されたゲノム改変 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| JP2022520402A (ja) | 2019-02-15 | 2022-03-30 | エディタス・メディシン、インコーポレイテッド | 免疫療法のための改変ナチュラルキラー（ｎｋ）細胞 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| DE112020001306T5 (de) | 2019-03-19 | 2022-01-27 | Massachusetts Institute Of Technology | Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US20220233593A1 (en) * | 2019-06-04 | 2022-07-28 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered t cells for immunotherapy |
| US20200407776A1 (en) * | 2019-06-26 | 2020-12-31 | Integrated Dna Technologies, Inc. | Compositions and methods for improved detection of genomic editing events |
| WO2021003462A1 (en) | 2019-07-03 | 2021-01-07 | Factor Bioscience Inc. | Cationic lipids and uses thereof |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| CN114340656B (zh) * | 2019-08-02 | 2024-07-30 | 孟山都技术公司 | 使用huh内切核酸酶促进靶向基因组修饰的方法和组合物 |
| WO2021050565A1 (en) * | 2019-09-09 | 2021-03-18 | Oregon Health & Science University | Crispr-mediated capture of nucleic acids |
| WO2021062267A1 (en) * | 2019-09-26 | 2021-04-01 | Nantbio, Inc. | Primary t-cell expansion |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN110904239B (zh) * | 2019-12-25 | 2020-11-10 | 武汉博杰生物医学科技有限公司 | 肺癌相关分子标志物基因突变的检测试剂盒与检测方法 |
| EP4100524A4 (en) * | 2020-02-05 | 2024-12-25 | Danmarks Tekniske Universitet | COMPOSITIONS AND METHODS FOR TARGETING, EDITING OR MODIFYING HUMAN GENES |
| EP4146800A1 (en) * | 2020-05-08 | 2023-03-15 | Metagenomi, Inc. | Enzymes with ruvc domains |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| BR112022023512A2 (pt) * | 2020-05-20 | 2022-12-20 | The Administrators Of The Tulane Educational Fund | Ensaio baseado em crispr para a detecção de patógenos em amostras. |
| US12012458B2 (en) | 2020-06-12 | 2024-06-18 | Nkarta, Inc. | Genetically modified natural killer cells for CD70-directed cancer immunotherapy |
| CA3198905A1 (en) * | 2020-10-19 | 2022-04-28 | Caribou Biosciences, Inc. | Dna-containing polynucleotides and guides for crispr type v systems, and methods of making and using the same |
| AU2021369840A1 (en) * | 2020-10-30 | 2023-06-01 | Arbor Biotechnologies, Inc. | Compositions comprising an rna guide targeting b2m and uses thereof |
| US20240026351A1 (en) * | 2020-10-30 | 2024-01-25 | Arbor Biotechnologies, Inc. | Compositions comprising an rna guide targeting trac and uses thereof |
| CN113881652B (zh) * | 2020-11-11 | 2022-11-22 | 山东舜丰生物科技有限公司 | 新型Cas酶和系统以及应用 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| JP2023552998A (ja) * | 2020-12-03 | 2023-12-20 | ンカルタ・インコーポレイテッド | 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用 |
| JP2023554651A (ja) * | 2020-12-17 | 2023-12-28 | モンサント テクノロジー エルエルシー | 操作されたｓｓＤＮａｓｅ不含ＣＲＩＳＰＲエンドヌクレアーゼ |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| KR102428773B1 (ko) * | 2021-04-21 | 2022-08-05 | (주)지플러스생명과학 | 분리형 crRNA 및 이를 이용한 CRISPR-Cas 시스템 |
| EP4362957A1 (en) | 2021-07-01 | 2024-05-08 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| WO2023028348A1 (en) * | 2021-08-27 | 2023-03-02 | Metagenomi, Inc. | Enzymes with ruvc domains |
| EP4437096A4 (en) | 2021-11-24 | 2025-09-24 | Metagenomi Inc | ENDONUCLEASE SYSTEMS |
| JP2023107748A (ja) * | 2022-01-24 | 2023-08-03 | 美洛生物科技股▲ふん▼有限公司 | 合成ｒｎａ断片及びｒｎａ依存性増幅のためのその使用 |
| TWI870769B (zh) * | 2022-01-24 | 2025-01-21 | 美洛生物科技股份有限公司 | 合成rna片段及其用於rna依賴擴增之用途 |
| WO2023164625A2 (en) * | 2022-02-25 | 2023-08-31 | Georgia Tech Research Corporation | Modified plant virus system for delivery of nucleic acids into mammalian cells |
| CA3259982A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics Inc | COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS |
| WO2024263564A2 (en) * | 2023-06-21 | 2024-12-26 | Lonza Cologne Gmbh | Multi-chambered electroporation cartridge and methods of use |
| WO2025213127A1 (en) | 2024-04-05 | 2025-10-09 | Indapta Therapeutics, Inc. | Treatment of autoimmune diseases or conditions with natural killer cells |
| WO2025245399A1 (en) | 2024-05-23 | 2025-11-27 | Indapta Therapeutics, Inc. | Method of treating cancer with natural killer cells |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2981617B1 (en) * | 2013-04-04 | 2023-07-05 | President and Fellows of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
| ES2883131T3 (es) * | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| DK3004337T3 (da) | 2013-05-29 | 2017-11-13 | Cellectis | Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system |
| ES2782125T3 (es) | 2014-03-11 | 2020-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
| WO2015161276A2 (en) * | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| WO2016073955A2 (en) * | 2014-11-06 | 2016-05-12 | President And Fellows Of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| BR112017020750A2 (pt) * | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP4108255A1 (en) * | 2015-10-05 | 2022-12-28 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
| JP2018536436A (ja) * | 2015-12-04 | 2018-12-13 | ノバルティス アーゲー | 免疫腫瘍学のための組成物および方法 |
-
2017
- 2017-03-03 SG SG11201807538PA patent/SG11201807538PA/en unknown
- 2017-03-03 CA CA3016331A patent/CA3016331A1/en active Pending
- 2017-03-03 JP JP2018546483A patent/JP7251980B2/ja active Active
- 2017-03-03 KR KR1020227029563A patent/KR102587132B1/ko active Active
- 2017-03-03 KR KR1020247039876A patent/KR20240173370A/ko active Pending
- 2017-03-03 CN CN201780027036.0A patent/CN109312340A/zh active Pending
- 2017-03-03 MX MX2018010484A patent/MX2018010484A/es unknown
- 2017-03-03 AU AU2017226172A patent/AU2017226172B9/en active Active
- 2017-03-03 KR KR1020237033935A patent/KR102738283B1/ko active Active
- 2017-03-03 KR KR1020187028616A patent/KR102438360B1/ko active Active
- 2017-03-03 EP EP17711928.6A patent/EP3423580A1/en active Pending
- 2017-03-03 WO PCT/US2017/020598 patent/WO2017152015A1/en not_active Ceased
- 2017-03-03 IL IL291971A patent/IL291971B2/en unknown
-
2018
- 2018-08-15 IL IL261163A patent/IL261163B2/en unknown
- 2018-08-30 MX MX2023007841A patent/MX2023007841A/es unknown
- 2018-09-04 US US16/121,152 patent/US12325854B2/en active Active
-
2023
- 2023-03-23 JP JP2023046534A patent/JP2023089005A/ja active Pending
- 2023-11-15 AU AU2023266284A patent/AU2023266284A1/en active Pending
-
2025
- 2025-05-06 US US19/200,416 patent/US20250320491A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507599A5 (enExample) | ||
| Hu et al. | CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia | |
| JP7516617B2 (ja) | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 | |
| Vijayakumar et al. | Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines | |
| Hu et al. | Nucleofection with plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells | |
| Zhang et al. | CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells | |
| JP7005346B2 (ja) | 養子細胞免疫療法の有効性を増強させるための組成物および方法 | |
| BR112020018658A2 (pt) | Composições de regulação gênica e métodos para imu-noterapia aprimorada | |
| IL292512B2 (en) | CRISPR-CAS-related methods, compositions and components for cancer immunotherapy | |
| JP2020509767A (ja) | 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用 | |
| JP2021518162A (ja) | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 | |
| JP2021518160A (ja) | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 | |
| JP2019503672A5 (enExample) | ||
| Tang et al. | Donor T cells for CAR T cell therapy | |
| JP2019531074A (ja) | マイナー組織適合性（ｈ）抗原ｈａ−１に特異的なｔｃｒ及びその使用 | |
| JP2019517788A (ja) | 遺伝子操作された細胞および同細胞を作製する方法 | |
| JP2024097924A (ja) | 抗ｐｔｋ７免疫細胞癌療法 | |
| JP2023105045A (ja) | Ｂｒａｆ特異的ｔｃｒおよびその使用 | |
| Fang et al. | Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy | |
| Morgan et al. | Chimeric antigen receptor T cells: extending translation from liquid to solid tumors | |
| Alsaieedi et al. | Tracing the development of CAR-T cell design: from concept to next-generation platforms | |
| CN113574174A (zh) | 用于增强的淋巴细胞介导的免疫治疗的组合物和方法 | |
| US20230233677A1 (en) | Compositions and methods for enhancing immune response | |
| US20250009800A1 (en) | Methods for cancer immunotherapy | |
| Hopkins et al. | Genome editing as a vehicle to drive successful chimeric antigen receptor T cell therapies to the clinic |